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Abstract
Background: Activated B cell-like subtype of diffuse large B cell lymphoma (ABC-DLBCL) presents aggressive clinical
courses and poor prognosis. Targeting key pathways may raise the possibility of improving clinical outcomes.
Methods: The synergetic effects were assessed by CCK-8 assay and measured by isobologram analysis. The NVP-Bez235
and lenalidomide cytotoxicity were measured by flow cytometry, Western Blot and si-RNA transfection. The combined
treatment inducing tumor regression in vivo was performed in nude mice of OCI-Ly10 xenograft mouse model.
Results: Low dose of two agents represented significant inhibition of proliferation with CI value < 1. NVP-Bez235
combined with lenalidomide remarkably increased apoptosis through intrinsic pathway by upregulating Bim, Bax
and downregulating Bcl-xL. Akt, especially NF-κB, played an important role in the synergetic effects. Cotreatment
also induced the cell cycle to be arrested in G0/G1 phase, and decreased S phase by increasing p21 expression,
downregulating cyclinA and diminishing CDK2 phosphorylation in Su-DHL2 and OCI-Ly3 but not in OCI-Ly10. Mice
treated with NVP-Bez235/lenalidomide represented obvious tumor growth regression and prolonged overall survival.
Conclusions: Our findings demonstrated the synergistic effect of low dose of NVP-Bez235 and lenalidomide in
ABC-DLBCL, the underlying mechanism may be multifunctional, involving apoptosis, Akt and NF-κB inactivation and
cell cycle arrest. Cotreatment was also effective in vivo. These data pave the way for potential treatment of ABC-DLBCL
with combination of NVP-Bez235 and lenalidomide.
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Background
DLBCL is the most common B-cell non-Hodgkin’s lymph-
oma (NHL), accounting for about 30–35 % of adults NHL
cases [1]. Nearly up to one-third patients suffered from re-
lapsed and refractory disease after R-CHOP (rituximab,
cyclophosphamide, doxorubicin, vincristine, prednisolone)
treatment [2], and limited patients got benefits from the
salvage strategy of autologous stem cell transplantation
(ASCT), indicating new agents are required to be tested in
this group of people.
However, the heterogeneity made DLBCL a complex
disease to handle with. DLBCL is considered to be
characterize into three major subtypes with distinct acti-
vating molecular pathways and different clinical outcomes
based on the gene expression profiling results [3]. Patients
with activated B cell-like (ABC) subtype, characterised as
constitutive NF-κB activation, were considered to have
lower progression free survival (PFS) rate and overall
survival (OS) rate compared with those with germinal
center B-cell (GCB) subtype or primary mediastinal B-cell
lymphoma (PMBL) [4]. Regarding of the participation of
NF-κB in many cell processes like tumor proliferation,
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invasion and inflammation, targeting NF-κB pathway has
become one of the promising therapeutic approach in
ABC-DLBCL treatment [5]. Directly interrupting NF-κB
pathway is one option of therapeutic strategy, and lenali-
domide, which is used as the immunomodulatory agent
treating multiple myeloma (MM), was proved to have
anti-tumor effects through downregulating IRF-4 in ABC-
DLBCL cell lines [6]. The selective anti-tumor effect of
lenalidomide in DLBCL is also supported by clinical
studies. Increasing evidence revealed that ABC-DLBCL
patients got better response with higher remission rate and
PFS rate when treated with lenalidomide alone or combin-
ation with R-CHOP regime [7, 8]. Meanwhile, lenalidomide
was found to have inhibiting function of tumor growth
through PI3K/Akt pathway, cereblon/p21, cyclin D1/p27
and Bcl-2 in chronic lymphocytic leukemia (CLL) and
mantle cell lymphoma (MCL) in pre-clinical experiments
[9–13]. Besides, it also showed effeciency when combined
with rituximab, dexamethasone and bortezomib in clinical
trials of treating several types of B-cell NHL [14, 15], which
implied the potential combination with other agents in
lymphoid hematological maliganancies.
Indirectly, interrupting the upstream of NF-κB could
also induce the inhibition of NF-κB pathway. It is known
that the constitutive NF-κB activation in ABC-DLBCL is
caused by individual or overlapping known mutations
like MYD88 L265P, CARD11, TNFAIP3 and CD79B/A
[16], which are involved in antigen-specific B-cell recep-
tor (BCR) and Toll-like receptor (TLR) induced NF-κB
activation. In the signaling cascade triggered by BCR,
several tyrosine kinases including PI3K, Bruton tyrosine
kinase (BTK) and mTOR are participated in, subse-
quently inducing the downstream pathways associated
with survival. NVP-Bez235 is one of the dual PI3K/
mTOR inhibitors that can suppress the activity of PI3K,
mTOR1 and mTOR2. It has shown anti-tumor activity
in a range of hematological malignancies including MM,
MCL, follicular lymphoma (FL), chronic lymphocytic
leukemia (ALL) and acute myelocytic leukemia (AML)
in the pre-clinical studies [17–21]. It was also reported
to synergize with agents such as MEK1/2 inhibitor [22].
Inhibition of mTOR could consequently decrease the
phosphorylation of P70S6 kinase as well as eukaryotic
translation initiation factor 4E binding protein 1 (4EBP1),
while PI3K activity represented an inexplicit relationship
with mTOR in the complex cell signaling circuits.
Collectively, the findings make us to explore the
efficacy of combined lenalidomide with NVP-Bez235
in treating ABC-DLBCL in vitro and in vivo. The
aim of the present study was to determine whether
lenalidomide could enhance the cytotoxic potency of
NVP-Bez235 in ABC subtype of DLBCL, and to
further elucidate the underlying mechanisms involved
in this effect.
Methods
Cells and cell culture
The non-GCB DLBCL derived cell lines OCI-Ly10,
OCI-Ly3 and Su-DHL2 were obtained from Dr. T
Zhao (Nanfang Hospital affiliated to Southern Medical
University, China). Cell lines were cultured in IMDM
(Invitrogen, Carlsbad, USA) with 10 % FBS (Invitrogen,
Carlsbad, USA), incubating in 37 °C with 5 % CO2.
Apoptosis assays
Cell apoptosis was determined by flow cytometry accord-
ing to the protocol of FITC Annexin V Apoptosis Detec-
tion Kit I (BD Bioscience, SanJose, CA, USA). Cells were
collected and washed by cold phosphoate-buffered saline
(PBS), then resuspended in Annexi-binding buffer and
sustained with propidium iodide (PI) and FITC Annexin
V. After incubating in the dark at room temperature for
15 min, cell suspensions were diluted by Annexin-binding
buffer and analysed by BD LSRFotessa flow cytometry
(SanJose, CA, USA) immediately. Data were acquired by
BD FACSDiva software (SanJose, CA, USA).
Cell proliferation assays
Analysis of cell proliferation was performed with cell
counting kit-8 (Dojindo, Japan) assay. NVP-Bez235 and
lenalidomide were purchased from Selleck (Huston, USA)
and dissolved in DMSO. The treatment of BEZ235 was
performed as 5nM, 10nM, 20nM and 40nM, while the
working concentration of lenalidomide were 0.5 μM, 1 μM,
2 μM and 4 μM. Cells were seeded in 96-well plate at a
concentration of 1 × 105/mL. After 72 h, 10uL cell counting
kit-8 were added to each well and incubated for 2 h. The
absorbance at 450 nm was measured by a microplate
reader. Growth inhibition was calculated by the formula
(O.D absorbance of treatment group – O.D absorbance of
blank)/(O.D absorbance of control group – O.D absorb-
ance of blank) × 100 %. The synergetic effect of two drugs
was measured by combination index (CI) using CalcuSyn
software (Version 2.1). CI < 1 indicates the synergetic effect,
CI = 1 means the additive effect and CI > 1 is regarded as
antagonism.
Immunobloting
NF-κB Pathway Sampler Kit, Akt, p-Akt (Ser 308), p-Akt
(Thr 473), p21, p-CDK2, CDK2, cyclinA, cyclinD1, mTOR
Pathway Sampler Kit, and Apoptosis sampler Kit were
obtained from Cell Signaling Technology (Beverly, MA,
USA). All the cell lines were treated with NVP-Bez235
and lenalidomide in single way or combination for 72 h.
Bortezomib was purchased from Selleck (Huston, USA).
Cells were performed with 5 nM Bortezomibe for 24 and
48 h, respectively. Then the samples in each group were
collected and separated by standard SDS-PAGE gel elec-
trophoresis and transferred to NC membrane. Blocked
Jin et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:52 Page 2 of 16
with 5 % non-fat milk supplemented in 0.1 % TBST,
membrane was probed with primary antibodies at 4 °C
overnight. After washed with TBST, membrane was incu-
bated with HRP-conjugated secondary antibodies (Santa
Cruz, CA) for one hour. The bands were detected and
quantified in Image Lab software (Bio-Rad Laboratories,
California, USA).
Gene silencing with siRNA
NF-κB siRNA were purchased from Santa Cruz (CA, USA).
Non-silencing siRNA was designed and synthesized as fol-
lowing: sense 5′-UUCUCCGAACGUGUCACGUTT-3′,
antisense 5′-ACGUGACACGUUCGGAGAATT-3′. Cell
lines were transiently transfected NF-κB siRNA and non-
silencing siRNA by using LipofectAMINE2000 reagent
(Invitrogen, Carlsbad, CA). After incubated for 8 h, lipid
containing siRNA was removed and warmed complete
medium was added. Cells were cotreated with NVP-
Bez235 and lenalidomide for another 48 h following 24-h-
transfection. Cells were collected for immunoblotting. Cell
viability was measured when cells were transfected for
24 h followed with 48 h.
Cell cycle assay
Each cell line was seeded in a 12-well plate exposing in
drugs for 72 h. Then the cells were collected, centri-
fuged, washed with ice-cold PBS and resuspended with
70 % alcohol. After fixed in -20 °C for 12 h, the cells
were washed and stained with PI and ribonuclease A
(Beytime Instituted of Biotechnology, China) at room
temperature for 30 min. Cell cycle data were assessed by
BD LSRFortes flow cytometry (SanJose, CA, USA) and
analyzed by Modfit LT 4.1 (Verity Software House,
Topsham, USA).
Mouse model
Six-weeks old nude female mice, purchased from Shanghai
Laboratory Animal Center (Shanghai, China), were injected
subcutaneously in the right flank with 1 × 107 OCI-Ly10
cells in 100 μL saline. When the tumor volume reached to
about 150–300 mm3, mice were randomly divided into 4
groups with 5 mice per group as follows: (I) control:
intraperitoneally injected with saline; (II) NVP-Bez235:
Bez235 20 mg/kg by oral gavage,dissoved in 10 % NMP
(1-methyl-2-pyrrolidone)/PEG 300 90 %, every other
day; (III) lenalidomide: intraperitoneally injected lenali-
domide 10 mg/kg/day (diluted in 4 % DMSO, 96 %
saline); (IV) combination: treatment of NVP-Bez235
with lenalidomide. The tumor volumes were measured
every other day by vernier caliper for 28 days and
calculated as V = a × b2/2(a, the length of tumor; b, the
width of tumor). At the end of observation, mice were
killed to remove the tumors. Then the samples were
fixed in 4 % formalin and further performed to frozen
section. Animal protocol was approved by the Animal
Care and Use Committee of Ruijin Hospital affiliated
to School of Medicine, Shanghai Jiao Tong University.
Immunohistochemistry
Fixed slides obtained from samples of nude mice were
incubated in 3 % H2O2 for 10 min to suppress endogen-
ous peroxidase activity and then washed in PBS. Next,
the slides were blocked with 1.5 % serum in PBS at room
temperature for 30 min and subsequently in BSA for
20 min. Then the slides were incubated with primary
antibodies p-NF-κB and Ki-67 (Santa Cruz, CA, USA)
overnight. After washed for 15 min, the slides were
added with secondary antibodies connected with biotin
for half an hour and incubated with SABC (Boster, Wu-
han, China). After incubating with a solution of DAB
(Boster, Wuhan, China), the tissue slides must be
checked under microscope to get appropriate staining.
The final steps were counterstaining, dehydrating, clear-
ing and mounting. The positive cells were counted using
Image-Pro plus 6.0 (Media Cybernetics, USA).
Terminal deoxytransferase-catalyzed DNA nick-end
labeling (Tunel) assay
Frozen sections were performed with a terminal trans-
ferase recombinant kit (Roche, Indianapolis, IN, USA)
under the guidelines of production information. Cells
with green fluorescence were termed as the apoptosis
section. Image-Pro plus 6.0 (Media Cybernetics, USA)
were used to analyze the positive cells in each slide.
Statistical analysis
All data in this study were analyzed with SPSS 17.0
software (Chicago, USA) and presented as mean ± stand-
ard deviation. Independent t test were used to determine
the significance of difference between groups. IC50 value
was analyzed by probit assay in SPSS. P < 0.05 was
considered as statistically significance Overall survival
was measured by Kaplan-Meier method. The drug inter-
actions were stated according to Chou-Talalay method
and isobologram analysis.
Results
Growth suppression of NVP-Bez235 and lenalidomide in
ABC subtype of DLBCL cell lines
We choose 3 cell lines of ABC-DLBCL according to the
public researches [6], which can partly represent the
ABC-DLBCL characters. All cell lines represented dose-
independent growth suppression when treated with
NVP-Bez235 or lenalidomide for 72 h (Fig. 1a, b). The
IC50 values of NVP-Bez235 were demonstrated in
Table 1. The proliferation inhibition was remarkably
increased when the dose of NVP-Bez235 was elevated.
In contrast, lenalidomide showed moderate inhibition
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and even 4 μM lenalidomide cannot reach the IC50 in
72 h. As the maximum observed plasma concentration
(Cmax) for patients treated with lenalidomide is 2.2 μM
[23], we did not set higher doses when determining the
cytotoxicity of lenalidimde in cell lines.
Low dose of lenalidomide and NVP-Bez235 displays
synergistic effect on ABC-DLBCL cell lines in vitro
All cell lines were treated with NVP-Bez235 (5nM, 10nM,
20nM and 40 nM) in combination with lenalidomide
(0.5 μM, 1 μM, 2 μM, 4 μM) for 72 h to determine the
Fig. 1 Combination effects of NVP-Bez235 and lenalidomide in proliferation inhibition. a, b Cell viability of Su-DHL2, OCI-Ly3, and OCI-Ly10 was
measured by CCK-8 assay after treated with NVP-Bez235 and lenalidomide alone or in combination for 72 h. Drugs were conducted simultaneously at
the indicated concentrations. c Isobologram analysis of agent combination at ED50 and CI values were calculated as well. d CI values of all cell lines at
ED25, ED50, ED75 and ED90. The lower CI values indicated the stronger synergism when CI < 1, and higher CI values means the stronger antagonism
when CI >1. Additive effect was designated with CI = 1
Jin et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:52 Page 4 of 16
combination effect. The growth inhibition was measured
by CCK-8 assay (Fig. 1a, b), and further analyzed using
isobologram analysis to validate the contributing effect of
drug combination (Fig. 1c). The CI value was identified
with 0.4 in Su-DHL2, 0.52 in OCI-Ly3 and 0.84 in OCI-
Ly10 when the effective dose of both drugs inhibited the
cell proliferation to 50 %. The low dose of lenalidomide
(0.5-2 μM) substantially enhanced the proliferation sup-
pression of NVP-Bez235 (5-20nM) with CI value ranging
from 0.3 to 0.8 (CI < 1), indicating the synergistic effects
of drug combination. In contrast, when lenalidomide
reached a concentration of 4 μM concomitant with the
concentration of NVP-Bez235 being at 40nM, the CI
values in all cell lines were above 1, suggesting an an-
tagonism effect of the drug combination (Table 2). As
demonstrated in Fig. 1d, the CI value raised when the
toxicity effects became higher. Specifically, the values
were lower than 1 at ED25 and ED50, around 1 at
ED75 and above 1 at ED90, which was in line with the
proliferation inhibition showed in Fig. 1a, b. Therefore,
the combination effect was correlated with the dose of
components. Low dose of lenalidominde in combin-
ation with low dose of NVP-Bez235 represented a syn-
ergistic effect in cell proliferation, whereas high dose of
two agents showed an antagonistic effect.
Combination of NVP-Bez235 and lenalidomide promote
the apoptosis through caspase activation and Bcl-2 family
regulation
To confirm whether the enhanced proliferation inhib-
ition was caused by apoptosis, all cell lines were ex-
posed to 20nM NVP-Bez235 and 2 μM lenalidomide
either in single way or in combination. As is shown
in Fig. 2a, b, apoptosis population was elevated from
36.5 % to 49.2 % under treatment of agent combin-
ation, which was significantly more than population
of those treated with single agents (p < 0.05). OCI-
Ly10 seemed less sensitive than OCI-Ly3 and Su-
DHL2 (Fig. 2c). The apoptosis induced by drug com-
bination was further confirmed by caspase family and
bcl-2 family identification. Robust increased cleavage
of caspase3 and poly-ADP-ribose polymerase (PARP)
was observed in the combination group after 72 h.
Subsequently, caspase 9 and caspase 8 were further
examined to identify whether the effect was trigged by
intrinsic or extrinsic signaling pathway. Our data showed
that cleaved-caspase 9 significantly increased accompanied
with the downregulation of total caspase 9 in the combin-
ation group. However, cleaved caspase 8 showed very
modest increase by cotreatment compared with the NVP-
Bez235 single treatment group, indicating the intrinsic
pathway plays a predominant role in the apoptosis trigged
by agent combination.
As the pivotal role of Bcl-2 family in the apoptosis
intrinsic pathway, pro-apoptosis members (Bax, Bad,
Bim) and anti-apopotosis members (Bcl-2 and Bcl-xL)
were selected to determine the disturbance induced
by single drug treatment or agents combination. Bim-
EL and Bim-S were elevated remarkably by drug com-
bination in all cell lines (Fig. 2d). The level of Bax
was obviously upregulated by drug combination especially
in Su-DHL2. However, we did not observe upregulation of
p-Bad to a greater extent in combination group compared
with NVP-Bez235 group. Among the anti-apoptosis
molecules, Bcl-xL was remarkably downregulated by drug
combination. Unlikely, Bcl-2 varied among cell lines.
Agent combination induced Bcl-2 downregulation in Su-
DHL2, upregulation in OCI-Ly3 and moderate change in
OCI-Ly10. The results indicated that apoptosis trigged by
drug combination was primarily mediated by intrinsic
apoptosis pathway, of which the pro-apoptosis members
overwhelmed the anti-apoptosis members.





CI 95 % 19.82–35.56
OCI-Ly3
IC50 27.39
CI 95 % 22.92–31.86
OCI-Ly10
IC50 36.86
CI 95 % 30.2–43.47
Table 2 Isobologram analysis of NVP-Bez235 in combination
with lenalidomide
Cell lines Bez235 (nM) Len (μM) CI
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Fig. 2 (See legend on next page.)
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Akt and NF-κB pathway contribute to growth inhibition
induced by drug combination
To further determine the mechanism of synergistic effect
of drug combination, the expression of p-Akt (Ser473)
and p-Akt (Thr308) was assessed by Western Blot. The
results represented that combined NVP-Bez235 and
lenalidomide significantly downregulated phosphorylation
of Akt (Ser 473, Thr 308) in Su-DHL2 and OCI-Ly3
compared with the single agent treatment and control
group, without affecting the total amount of Akt. In OCI-
Ly10, phosphorylation of Akt (Ser 473) was totally blocked
by NVP-Bez235 and combination components, while
phosphorylation of Akt (Thr 308) only slightly reduced by
Bez235 and drug combination (Fig. 3a).
The results led us to further examine whether inhibition
was similar in the NF-κB pathway. Our study revealed that
(See figure on previous page.)
Fig. 2 NVP-Bez235 combined with lenalidomide significantly increased the apoptosis in all cell lines. a, b Cell lines were simultaneously treated with
NVP-BEZ235 (20nM) and lenalidomide (2 μM) for 72 h, analyzing apoptosis by Annexin-V/PI staining with t test statistic assay. (Mean ± S.D., n = 3,
*, +, # p < 0.05, **, ++, ## p < 0.01, ***, +++, ### p < 0.005 compared with control group) (c) Cell lines were subjected to indicated treatments and
protein lysates were performed with immunoblotting, incubating with PARP, caspase3, caspase9, caspase8 and their cleavage formate antibodies.
d Cell extractions were conducted with Western Blot to detect Bcl-2 family members including Bax, Bad, p-Bad, Bim, Bcl-2 and Bcl-xL
Fig. 3 Synergistic inhibition of AKT and NF-κB pathway. a Cell lines were treated with NVP-Bez235 20nM and lenalidomide 2 μM alone or in combination
for 72 h. Western blot analysis was performed to identify the expression of total Akt, p-Akt (Ser 473) and p-Akt (Thr308). b Western blot for Ikkα, Ikkβ,
p-Ikkα/β, IΚBα, p-IΚBα, NF-κB and p-NF-κB
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the expression of p-IKKα/β, p-NF-κB and p-IΚBα were di-
minished to some extent after that the cell lines were ex-
posed to single agent for 72 h, indicating using NVP-
Bez235 or lenalidomide alone is not sufficient to block the
NF-κB pathway. Unlikely, robust suppression of these
molecules was observed in combined treatment of NVP-
Bez235 and lenalidomide (Fig. 3b). In order to determine
whether NF-κB plays a functional role in cotreatment
anti-DLBCL activity, bortezomib, the first protesome in-
hibitor, was performed in the concentration at 5nM for
24 h and 48 h in all cell lines. Treatment with bortezomib
represented significant downregulation of p-NF-κB with
the cell viability reducing to 56.7 % and 72.8 % in Su-
DHL2 and OCI-Ly3 respectively, which was not as strong
as the combined treatment (p < 0.05) (Fig. 4a, b). However,
the reduction of cell viability by agents combination
seemed the same as bortezomib treatment in OCI-Ly10
after 72 h with no statistical significance (p > 0.05) (Fig. 4b),
indicating the NF-κB pathway may play a more essential
role in the apoptosis induced by NVP-Bez235 and lenali-
domide in OCI-Ly10 than in Su-DHL2 and OCI-Ly3. To
validate the role of NF-κB in drug induced apoptosis, Si-
RNA of NF-κB was transfected to all cell lines. As is
shown in Fig. 4c, knockdown of NF-κB protected cell lines
from apoptosis with the reduction of caspase 3 cleavage
compared with the non-silence siRNA group in all cell
lines. Similarly, knockdown of NF-κB rendered cells more
resistant to single agent or combination treatment
(Fig. 4d). Taken together, we could conjecture that NF-κB
pathway contributed to the apoptosis, but blocking NF-κB
could not restore proliferation inhibition, suggesting other
mechanisms may also contribute to cytotoxicity induced
by drug combination.
NVP-Bez235 and lenalidomide combination arrested
cell-cycle in G0/G1 phase
According to the results of proliferation inhibition
above, cell-cycle detection was carried out under the
treatment of indicated concentration to understand the
synergism mechanism triggered by NVP-Bez235 and
lenalidomide. The fraction of cells in S phase was signifi-
cantly decreased by combination treatment (p = 0.009 in
Fig. 4 The role of NF-κB in apoptosis induced by NVP-Bez235 and lenalidomide. a Cell lines were exposed to 5nM bortezomib for 24 h and
48 h, respectively. Cell lysis were conducted with immunoblotting for p-NF-κB and NF-κB. b Bar graph was represented as mean ± S.D (*p< 0.05) to show
the cell viability of cell lines treated with 5nM bortezomib and concomitant treatmemt of NVP-Bez235 (20nM) and lenalidomide (2 μM). c All cell lines were
transiently transfected with siRNA against NF-κB (si-NF-κB) and nonsilencing siRNA (si-NS) respectively for 24 h and then exposed to NVP-Bez235 (20nM)
plus lenalidomide (2 μM) for 48 h. Then cells were collected for Western blot. d Cells were transfected as (c) for 24 h and treated with compounds for
another 48 h. Then CCK-8 assay was performed to calculate the cell viability. *p< 0.05, **p< 0.01, ***p< 0.005 compared with si-NS group
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Su-DHL2, p = 0.002 in OCI-Ly3) compared with the
DMSO group, accompanied by the increase of G0/G1
phase. There was no change in G2/M phase after cell
cycle interfered with single agent or combination. In
OCI-Ly10, drug combination did not increase G0/G1
phase or decrease S phase compared with NVP-Bez235
alone (Fig. 5a, b). Western blot was further performed to
confirm the checkpoints associated with cell cycle. Com-
bination of NVP-Bez235 and lenalidomide noticeably
downregulated the expression of cyclinA and p-CDK2 in
Su-DHL2 and OCI-Ly3, but not in OCI-Ly10 compared
with the single agent treatment and control group
(Fig. 5c), which was in accordance with the results of
flow cytometry (Fig. 5a). Lenalidomide did not enhance
the NVP-Bez235 function by upregulating cyclinD1.
Meanwhile, lenalidomide significantly increased p21 ex-
pression in Su-DHL2, while NVP-Bez235 exerted similar
effect in OCI-Ly3. By cotreatment, p21 was noticeably
accumulated in both cell lines. In OCI-Ly10, p21 was
not affected by drug treatment.
Cotreatment of NVP-Bez235 and lenalidomide inhibit the
mTOR pathway in vitro
As NVP-Bez235 was also the inhibitor of mTOR, we fur-
ther determined whether the mTOR pathway contributed
to synergism. As is shown in Fig. 6, mTOR pathway was
totally abrogated by NVP-Bez235 combined with lenalido-
mide. The expression of total 4EBP1 was also reduced by
cotreatment. These data suggested that mTOR pathway
may also be involved in the synergetic effect in vitro.
Combined low dose of NVP-Bez235 and lenalidomide
suppressed tumor growth and prolonged the overall
survival of the xenograft model of DLBCL
The cytotoxic effect of NVP-Bez235 and lenalidmide alone
or in combination were evaluated in the nude mice bearing
OCI-Ly10 tumors. Mice were treated with NVP-Bez235
20 mg/kg in gavage, lenalidomide 10 mg/kg intraperitone-
ally or the combination. Tumor volumes in each group are
shown in Fig. 7a. Daily treated with lenalidomide alone did
not result in tumor growth delay (p > 0.05), whereas treat-
ment of NVP-Bez235 alone significantly suppressed tumor
growth compared with saline injection from 10 day onward
(p < 0.001). Furthermore, lenalidomide enhanced the effect
of tumor suppression of NVP-Bez235 when compared with
NVP-Bez235 treatment (p < 0.01). All treatments were well
tolerated with less body weight (<10 %) and no toxic death.
Overall survival was prolonged after observation for 60 days
with the median survival of 37 days in saline group, 57 days
in NVP-Bez235 group and 41 days in lenalidomide group
(p < 0.0001) (Fig. 7b). There was no death observed in the
drug combination group at the end point of observation.
To confirm our studies of growth suppression mech-
anism, immunohistochemical analysis was conducted to
identify the expression of Ki67 and p-NF-κB in each
cohort. Combined treatment reduced the positive cells
of Ki67 compared with control group (p < 0.01) and
NVP-Bez235 group (p = 0.005) (Fig. 7d). While it seemed
that lenalidomide moderately enhanced tumor suppression
induced by NVP-Bez235 according to the comparison of
Ki67 expression with NVP-Bez235 and cotreatment group
(p = 0.04 < 0.05). Cotreatment of NVP-Bez235/lenalidomide
also increased the apoptosis (p < 0.001), revealed by Tunnel
assay (Fig. 7f), which matched our previous studies in vitro.
Although the positive cells stained with p-NF-κB were ob-
viously reduced by NVP-Bez235 (p < 0.001), the drug com-
bination did not enhance repression compared with the
NVP-Bez235 group to a greater extent (p = 0.023 < 0.05)
(Fig. 7e), which is not as effective as it did in vitro. Our
results suggested that NVP-Bez235 combined with lenali-
domide could remarkably delay the tumor growth by indu-
cing apoptosis and inhibiting proliferation in vivo, but the
mechanism of this suppression may be caused by multiple
pathways including downregulation of p-NF-κB.
Discussion
Combination strategy has represented lower toxicities and
overcoming agent resistance in treatment of DLBCL. The
oncogenetic molecular mechanisms involved in ABC-
DLBCL were primarily initiated by BCR subunit activated
mutations, as well as the CARD11 and MYD88 mutations,
resulting in the constitutive activation of NF-κB [16, 24].
Meanwhile, constitutive PI3K signaling activation, resulted
from the chronic BCR activation, was proved to support
the viability of ABC-DLBCL [25]. For this reason, target-
ing proteins involved in these pathways is a rationale way
in treating ABC-DLBCL. NVP-Bez235, a dual mTOR/
PI3K inhibitor, was found to synergistically interact with
BTK inhibitor Ibrutinib [26] and HDAC inhibitors [27]. In
our study, we demonstrated that combination of low dose
of NVP-Bez235 and lenalidomide played synergistic roles
in killing ABC-DLBCL cells.
ABC-DLBCL cell lines showed different sensitivity to
NVP-Bez235 and lenalidomide. Su-DHL2 and OCI-Ly3
were more vulnerable to single agent, but OCI-Ly10
showed a little resistant. Investigations of the direct
cytotoxicity of lenalidmide in DLBCL [6, 28] have
supported our findings. This difference also resulted in
the variety in antiproliferation of combination treatment
with different doses. The antagonistic effect appeared
when drug doses escalated to higher level in all cell lines.
Importantly, the synergistic effect was maintained when
the concentrations of both drugs were well below clin-
ical Cmax [23, 29]. It was reported that NVP-Bez235 has
no toxicity in normal CD34+ hematopoietic cells [27],
and lenalidomide has limited long-term toxicity [30],
suggesting the potential clinical application value of this
combination strategy. We then examined the apoptosis
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Fig. 5 The effect of NVP-Bez235 and lenalidomide in cell cycle. a Cell lines were treated with components for 72 h, collected and fixed by 70 %
ethanol for 24 h. Cell cycle assay was assessed with cytometry and Modfit LT. b The Bar graph illustrated the proportion of G0/G1 phase, S phase,
G2/M phase of cell lines treated as mentioned above. Era bars indicated the standard deviation (n = 3). *, # p < 0.05, **, ## p < 0.01, ***, ### p < 0.005
compared with control group. c Western blot for cell lysis collected after treated with single agent or combination agents for 72 h
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induced by drug combination, and the results are in ac-
cordance with our previous findings. The apoptosis
proportion of OCI-Ly10 was not as much as those of
Su-DHL2 and OCI-Ly3. The difference of toxicity may
be explained, at least partly, with the heterogeneity of
DLBCL. OCI-Ly3 and OCI-Ly10 both maintain the
MYD88-L256P mutation while Su-DHL2 gets the
mutation of MYD88-S222R [16]. Meanwhile, mutation
of CARD11, which induces the activation of IKK2 and
NF-κB, also existed in OCI-Ly3 but not in OCI-Ly10
[24], and mutation of TNFAIP3/A20 was observed in
Su-DHL2 [31]. Collectively, the various mutation statues
in each cell lines may be the underlying reasons of the vari-
ous responses to single agent treatment or drug combin-
ation. In order to explain the different toxicity responses,
we further examined the intrinsic pathway and extrinsic
pathway, and found that apoptosis intrinsic pathway played
a predominant role in the synergistic effect. To date, the
complex process of apoptosis could be mainly categorized
into intrinsic and extrinsic pathway, finally resulting in the
DNA fragmentation and cell death. Stimulations from
extracellular activated the transmembrane receptor and
consequently triggered the activation of extrinsic initiator
of caspase 8. In contrast, intrinsic pathway was initiated by
mitochondrial events and resulted in the activation of cas-
pase 9 through a more complex procedure. Finally, both
extrinsic and intrinsic pathways would go through the
execution pathway, which is considered as the end point of
apoptosis. Caspase 3 is regarded as the most essential
effector in the apoptosis execution pathway. Once it is
activated by caspase 8 or caspase 9, the activated caspase 3
will further induce the cleavage of various subtracts such
as PARP, which is a nuclear DNA-binding protein
functioning as DNA breaks detector. The mitochondrial
events of intrinsic pathway taken place in and controlled
by Bcl-2 family, which can group into proapoptotic mem-
bers and antiapoptotic members. At the initiation, Bim
plays a crucial role [32]. Subsequently, oligomerization of
Bak and Bax permeabiliaze the mitochondrial membrane
and release SMAC and cytochrome c, further activating
caspase9 and finally inducing apoptosis. The Bim up-
regulation was required in the synergy of lenalidomide and
NPI-0052 in MM [33], as well as in the contributing effect
of NVP-Bez235 and HDAC inhibitor in DLBCL [27]. Here
our results also showed that combined NVP-Bez235 and
lenalidomide resulted in the accumulation of Bim-S, Bim-
EL isoforms and Bax. Bad, a member of BH3-only protein,
was regarded to exhibit the proapoptosis functions by dir-
ectly binding and inhibiting anti-apoptotic member Bcl-2
and was reported to be associated with the DBLCL tumori-
genesis [34]. We did not find stronger phosphorylation of
p-Bad in the combination treatment, suggesting other
members may exert more important efforts in the apop-
tosis. We next identified the dysregulation of anti-apoptotic
members including Bcl-2 and Bcl-xL. The Bcl-xL expres-
sion was significantly reduced by drug combination. How-
ever, the Bcl-2 expression varied among the cell lines. One
reason may partly explain the chaos of Bcl-2. The onco-
genic function of Bcl-2 was first reported as its overexpres-
sion could promote the c-myc driven proliferation [35].
Patients who suffered with the “double-hit” DLBCL, repre-
senting the translocation of MYC with the arrangements of
BCL2, BCL6 or CCND1, often turn out to be with poor
prognosis [36]. C-MYC amplification was found in OCI-
Ly3 but not in OCI-Ly10 [37], and there was no report on
the C-MYC status in Su-DHL2. These led us to assume
that the diverse of MYC expression in cell lines causes the
Bcl-2 variation in different cell lines. We did not examine
the change of anti-apoptotic member Mcl-1 induced by
drug combination. To our knowledge, Mcl-1 was elevated
in ABC-DLBCL [38], and many pre-clinical studies have
reported its necessity in drug-induced apoptosis of DLBCL
[27, 39, 40]. Altogether, our results demonstrated that the
drug combination induced the apoptosis through the
Fig. 6 Combination treatment affected mTOR pathway. All cell lines were treated with NVP-Bez235 and lenalidomide for 72 h. Cell lysis was determined
by immunoblotting to identify the protein mTOR, p-mTOR, p70S6K, p-p70S6K, 4EBP1, and p-4EBP1
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Fig. 7 (See legend on next page.)
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intrinsic pathway by elevating the cleaved-caspase 9,
Bim and Bax, as well as downregulating the expres-
sion of Bcl-xL.
The mechanism involved in the synergetic effect was fur-
ther depicted by examination of Akt and NF-κB pathway.
Since lenalidomide was reported to exert its immunomod-
ulatory function through PI3K/Akt pathway in CLL [11],
we found that lenalidomide only slightly dephosphorylated
p-Akt (Ser 473) in OCI-Ly10 and p-Akt (Thr 308) in Su-
DHL2, which in line with the study of lenalidomide cyto-
toxicity in MCL [41]. Robust downregulation of p-Akt (Ser
473) and p-Akt (Thr 308) was observed in Su-DHL2 and
OCI-ly3 by co-treatment, indicating the importance of
PI3K/Akt in the synergetic effect. The activation of NF-κB
was well considered to support the viability of ABC-
DLBCL. Recurrent somatic mutations resulted in the activ-
ity of NF-κB varied among cell lines, of which MYD88-
L256P got higher NF-κB activity than MYD88-S222R [16].
Specifically, the expression of NF-κB, p-p65 and p52 was
predicted to be a poor prognosis factor of DLBCL in some
studies [42, 43], as well as the p-IΚBα in ABC-DLBCL [44],
but the expression of Rel was reported to be associated
with superior clinical outcome [45]. Tracing the validation
of NF-κB pathway in prognosis, function of NF-κB was
estimated to cooperate with FOXP1 and BLIMP1 in ABC-
DLBCL [46, 47]. Abundant researches indicated that NF-
κB monitored the cell life and death through regulating
apoptosis program in a caspase-independent way [48].
Regarded as an anti-apoptosis transcription factor, NF-κB
could induce a number of gene expressions, of which the
production acts as the apoptosis inhibitor. C-IAPs and c-
FLIP are well established NF-κB-regulated proteins.
Besides, NF-κB was also found to modulate the Bcl-2 fam-
ily and pro-/anti-apoptosis pathways through TRAF1 and
TRAP2 [49]. Owing to the important role of NF-κB in cell
fate, members involved in the NF-κB pathway were further
detected. We found that NVP-Bez235 and lenalidomide
treatment also substantially downregulated NF-κB pathway.
However, we did not assess whether suppression of Akt
activity was involved in the regulation of NF-κB, but it
seemed that PI3K could only directly affect high level of
nuclear NF-κB in DLBCL cell lines [25]. In contrast, other
studies indicated that NF-κB was controlled by PI3K [50,
51]. In addition, as NVP-Bez235 also inhibited the mTOR
pathway, whether NF-κB is independent with mTOR path-
way requires further study. Of note, our confirmation of
the role of NF-κB in synergetic effect also implied that the
mechanism could not be simply explained by the inhibition
of Akt and NF-κB pathways, so there must be other
biological impacts contributing to this effect.
Cell cycle arrest has been observed in the anti-NHL
and anti-CLL activity of PI3K inhibitor as well as lenali-
domide [12, 41, 52–54]. In our study, sharp decrease of
S phase was observed in Su-DHL2 and OCI-Ly3 cell
lines with apparently increase of G0/G1 phase after ex-
posed in both NVP-Bez235 and lenalidomide, suggesting
the cell cycle arrest contributed to the combined cyto-
toxicity. Furthermore, in view of importance of CDK2/
cyclinA in G1/S phase transition [55], abrogation of
cyclinA and dephosphorylation of p-CDK2 in Su-DHL2
and OCI-Ly3 by cotreatment may contribute to the ul-
timate cell death. Indeed, deregulation of CDK2 and
CDK4 genes has been found to be associated with the
transformation process of the transformed DLBCL [56],
additionally, CDKN2A deletion was predicted for poor
prognosis in DLBCL [57], suggesting the important role
of CDK2 in pathogenesis of DLBCL. It was known that
p21 and p27 normally arrest cell cycle by suppressing
the activity of CDKs, but we did not examine the expres-
sion of p27. p21 could be upregulated by lenalidomide
[12], which is in line with our studies, and was even
associated with prognosis, for example, p53 + p27 + p21-
p16- and low p27 expression was suggested with poor
clinical outcomes and shorter survivals [58, 59].
CyclinD1 was accumulated by NVP-Bez235/lenalido-
mide cotreatment, which is in contrast with the results
of lenalidomide in MCL [41]. The overexpression of
cyclinD1 in DLBCL, accounting for 1.5–15 % [60–62],
showed no prognosis value [63], indicating the cyclinD1
may not be as important as cyclinA/CDK2. The mech-
anism by which Akt or NF-κB inhibition diminish
cyclinA or p-CDK2 in our study is unclear, but Chiron
et al reported that PI3K inhibitors induced cell cycle
arrest by downregulating CDK4/6 [64], and NF-κB was
reported to be associated with cell cycle regulation [65].
Finally, our in vivo studies demonstrated that concomi-
tant treatment of NVP-Bez235 and lenalidomide exerted
potential antitumor activitity with well tolerant doses.
(See figure on previous page.)
Fig. 7 NVP-Bez235 plus lenalidomide dramatically inhibited tumor growth and prolonged the survival in a DLBCL xenograft mouse model (OCI-Ly10).
a Mice in each cohort were treated with lenalidomide (10 mg/kg) every other day and NVP-Bez235 (20 mg/kg/day) alone or in combination. Tumor
volumes were measured every other day for 28 days. At the end of observation, tumor growth was significantly delayed by combination treatment
compared with control group (***p = 0.0003) and NVP-Bez235 treatment group (**p = 0.006). b Overall survival was prolonged by NVP-Bez235 and
lenalidomide combination therapy compared with the control group and single agent group (p < 0.0001). c IHC to identify expression of
Ki67, p- NF-κB of tumor specimen Tunnel assay was performed to examine the apoptosis in tissues. d, e, f Bar graph illustrate the proportion of positive
cells showed in panel C. *p < 0.05, **p <0.01, *** p < 0.005 compared with the control group
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Specifically, although lenalidomide single treatment did not
show anti-DLBCL activity in vivo, it significantly enhanced
NVP-Bez235 antitumor potency by delaying the tumor
growth and prolonging the overall survival. Moreover, the
apoptosis and growth inhibition with cotreatment in vitro
could also be detected in tumor tissues. Unlikely, NVP-
Bez235/lenalidomide cotreatment did not inhibit the phos-
phorylation of p-NF-κB to a great extent as it did in in vitro
studies, suggesting that the mechanism of antitumor activ-
ity in intact animals may be more complex than the mech-
anisms in vitro.
Conclusions
Collectively, our study demonstrated that NVP-Bez235
combined with lenalidomide effectively inhibited cell pro-
liferation, induced apoptosis and cell cycle arrest in ABC-
DLBCL cell lines. Moreover, it was also active in the
DLBCL xenograft model. The present findings also suggest
that the mechanisms are likely associated with regulation
of Akt and NF-κB pathway, inducing the apoptosis through
upregulation of Bim, Bax and downregulation of Bcl-xL in
all cell lines. Lenalidomide did not enhance the potency of
NVP-Bez235 in OCI-Ly10 by inhibiting G1/S transition
withincreasing p21 expression, downregulating cyclinA
and dephophorylating p-CDK2. Notably, NF-κB may also
be related to the drug resistance of DLBCL [66]. Therefore,
our present studies raise the possibility of a novel strategy
to treat ABC-DLBCL patients by using the combination of
NVP-Bez235 and lenalidomide.
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